Motilal Oswal has picked UTI AMC, Galaxy Surfactant, and P&G Hygiene and Healthcare (P&GHH). According to the latest brokerage view, some of these stocks have upside potential of up to 34%.
A look at the key details –
Motilal Oswal on UTI AMC: Potential of up to 26% as performance significantly
Motilal Oswal reiterated a ‘Buy’ on UTI AMC after the company’s performance over the last five months improved considerably, with an average of 70% equity AUM appearing in Q1 and Q2 on a one-year return basis in May 2025 against an average of 25% in the preceding 12 months.
“This, we believe, can drive equity market share gains, which have been stable at 3.9% over the past seven months,” said Motilal Oswal.
Over FY25-27, the brokerage house expects UTI AMC to report an AUM growth of 17%, a revenue increase of 13%, and core net profit of 20%. The sustained strong performance has been a key re-rating driver for AMC stocks. Also, Motilal Oswal sees that UTI AMC is trading at a higher discount to other players over the past few months. The brokerage firm has a target price of Rs 1,550 on UTI AMC, seeing a potential upside of up to 26%.
Motilal Oswal on Galaxy Surfactants: Last decade demonstrated exceptional growth
Over the past 10 years, Galaxy Surfactants has demonstrated its ability to scale profitably while navigating cyclical and regional challenges, said Motilal Oswal in a research note.
During FY15-25, the company doubled its total volumes, supported by deeper market penetration and category expansion. It was particularly in rinse-off personal care and home care products. In the last decade, EBITDA tripled, which was driven by operational efficiencies, product mix enhancement, and innovation. Galaxy Surfactants’ net profit rose 5 times, reflecting sharp execution and cost control.
The brokerage house expects a volume growth of 6% (CAGR) over FY25-27, driven by improving volumes in the Speciality Care segment across developed markets and a recovery in demand from rural and urban markets in India. Motilal Oswal reiterated a ‘Buy’ rating on the stock. It has a target price of Rs 3,180 on Galaxy Surfactants, seeing an upside of up to 34%.
Motilal Oswal on P&GHH: Feminine Hygiene and Healthcare are key growth categories
Motilal Oswal retained its ‘Neutral’ rating on P&GHH, with a target price of Rs 15,000. This is an upside of 12%. The brokerage said that the company’s strategic pillars that drive growth in the Personal and Healthcare categories are intact. The company holds a dominant market share in both the Feminine Hygiene and Healthcare categories. It has a market share of 50% in these categories.
Adding to that, P&GHH continues to expand its portfolio through product innovation (like Vicks VapoRub Steam Pods, Vicks Cough Syrup, and Whisper Super Absorbent Period Panty).
For Motilal Oswal PGHH’s two factors make it an attractive long-term core holding. The first one is robust growth potential in the Feminine Hygiene segment (65-68% mix of FY24 sales), along with opportunities for market share gains, supported by strategic initiatives, including the fortification of significant market advantages. Secondly, potential for higher margin gains from the long-term trend of premiumisation in the Feminine Hygiene segment.